Novo Nordisk A/S Will Boost China Investments to Fend Off Sanofi (France), COO Says

Novo Nordisk A/S will boost investments in China to preserve its dominance in the world’s largest market after rival Sanofi made a new foray amid an effort by the government to improve health services.

“We don’t fear any competition,” said Kaare Schultz, chief operating officer for Bagsvaerd, Denmark-based Novo, the world’s biggest maker of insulin.

Back to news